Research programme: gene therapies - HuidaGene Therapeutics
Latest Information Update: 08 Feb 2023
Price :
$50 *
At a glance
- Originator HuidaGene Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene modulators; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Ear disorders; Eye disorders; Neurological disorders
Most Recent Events
- 02 Feb 2023 Early research in Ear disorders in China (unspecified route) (Huidagene Therapeutics pipeline, February 2023)
- 02 Feb 2023 Early research in Neurological disorders in China (unspecified route) (Huidagene Therapeutics pipeline, February 2023)
- 02 Feb 2023 Preclinical trials in Eye disorders in China (unspecified route) (Huidagene Therapeutics pipeline, February 2023)